Loading...
XNAS
SCYX
Market cap27mUSD
Dec 05, Last price  
0.66USD
1D
-2.00%
1Q
-26.34%
Jan 2017
-79.45%
IPO
-92.56%
Name

SCYNEXIS Inc

Chart & Performance

D1W1MN
XNAS:SCYX chart
P/E
—
P/S
7.34
EPS
—
Div Yield, %
—
Shrs. gr., 5y
53.96%
Rev. gr., 5y
98.68%
Revenues
4m
-97.33%
16,837,00016,857,0001,256,000257,000257,000257,000257,000121,000013,163,0005,091,000140,141,0003,746,000
Net income
-21m
L
-11,477,000-30,461,000-4,234,000-32,623,000-29,989,000-25,060,000-12,468,000-55,234,000-55,185,000-32,866,000-62,809,00067,041,000-21,288,000
CFO
-24m
L
-10,596,000-4,307,000-9,472,000-24,545,000-29,353,000-24,556,000-28,323,000-38,119,000-49,354,000-54,560,000-79,883,00060,159,000-24,009,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
URL
https://www.scynexis.com/
IPO date
May 02, 2014
Employees
36
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT